- Bastard, Paul
- Gervais, Adrian
- Taniguchi, Maki
- Saare, Liisa
- Särekannu, Karita
- Voyer, Tom Le
- Philippot, Quentin
- Rosain, Jérémie
- Bizien, Lucy
- Asano, Takaki
- Garcia-Prat, Marina
- Parra-Martínez, Alba
- Migaud, Mélanie
- Tsumura, Miyuki
- Conti, Francesca
- Belot, Alexandre
- Rivière, Jacques G.
- Morio, Tomohiro
- Tanaka, Junko
- Javouhey, Etienne
- Haerynck, Filomeen
- Duvlis, Sotirija
- Ozcelik, Tayfun
- Keles, Sevgi
- Tandjaoui-Lambiotte, Yacine
- Escoda, Simon
- Husain, Maya
- Pan-Hammarström, Qiang
- Pérez-Tur, Jordi
- Planas, Anna M.
- Hammarström, Lennart
- Ahlijah, Gloria
- Haidar, Anthony Abi
- Soudee, Camille
- Arseguel, Vincent
- Abolhassani, Hassan
- Sahanic, Sabina
- Tancevski, Ivan
- Nukui, Yoko
- Hayakawa, Seiichi
- Chrousos, George P.
- Michos, Athanasios
- Tatsi, Elizabeth Barbara
- Filippatos, Filippos
- Rodriguez-Palmero, Agusti
- Troya, Jesus
- Tipu, Imran
- Meyts, Isabelle
- Roussel, Lucie
- Ostrowski, Sisse Rye
- Schidlowski, Laire
- Prando, Carolina
- Condino-Neto, Antonio
- Cheikh, Nathalie
- Bousfiha, Ahmed A.
- Bakkouri, Jalila El
- Peterson, Pärt
- Pujol, Aurora
- Lévy, Romain
- Quartier, Pierre
- Vinh, Donald C.
- Boisson, Bertrand
- Béziat, Vivien
- Zhang, Shen Ying
- Borghesi, Alessandro
- Pession, Andrea
- Andreakos, Evangelos
- Marr, Nico
- Mentis, Alexios Fotios A.
- Mogensen, Trine H.
- Rodríguez-Gallego, Carlos
- Soler-Palacin, Pere
- Colobran, Roger
- Tillmann, Vallo
- Neven, Bénédicte
- Trouillet-Assant, Sophie
- Brodin, Petter
- Abel, Laurent
- Jouanguy, Emmanuelle
- Zhang, Qian
- Martinón-Torres, Federico
- Salas, Antonio
- Gómez-Carballa, Alberto
- Gonzalez-Granado, Luis I.
- Kisand, Kai
- Okada, Satoshi
- Puel, Anne
- Cobat, Aurélie
- Casanova, Jean-Laurent
- Aguilera-Albesa, Sergio
- Alkhater, Suzan A.
- Alkan, Gulsum
- Castagnoli, Riccardo
- Cyrus, Cyril
- Bozdemir, Sefika Elmas
- Emiroglu, Melike
- Gulhan, Belgin
- Erdeniz, Emine Hafize
- Hatipoglu, Nevin
- Bayhan, Gülsün Iclal
- Jabandziev, Petr
- Yuksek, Saliha Kanik
- COVID Human Genetic Effort
We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7–9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2–5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6–35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1–9.6]) of IFN-ω and/or IFN-α2., The Laboratory of Human Genetics of Infectious Diseases
is supported by the Howard Hughes Medical Institute, the
Rockefeller University, the St. Giles Foundation, the National
Institutes of Health (NIH) (R01AI088364, R01AI163029, and
R21AI160576), the National Center for Advancing Translational
Sciences, the NIH Clinical and Translational Science Award
program (UL1TR001866), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation,
the Stavros Niarchos Foundation Institute for Global Infectious Disease Research, the program “Investissement d’Avenir”
launched by the French Government and implemented by the
Agence Nationale de la Recherche (ANR) (ANR-10-IAHU-01), the
Integrative Biology of Emerging Infectious Diseases Laboratory
of Excellence (ANR-10-LABX-62-IBEID), the French Foundation
for Medical Research (FRM) (EQU201903007798), the ANRSCOV05, ANR GENVIR (ANR-20-CE93-003), ANR AI2D (ANR-22-
CE15-0046), and ANR AAILC (ANR-21-LIBA-0002) projects,
the European Union’s Horizon 2020 research and innovation
program under grant agreement no. 824110 (EASI-genomics),
the HORIZON-HLTH-2021-DISEASE-04 program under grant
agreement 01057100 (UNDINE), the ANR-RHU COVIFERON
Program (ANR-21-RHUS-08), the Square Foundation, Grandir -
Fonds de solidarite pour l ´ ’enfance, the Fondation du Souffle, the
SCOR Corporate Foundation for Science, The French Ministry of
Higher Education, Research, and Innovation (MESRI-COVID-19),
Institut National de la Sante et de la Recherche M ´ edicale (IN- ´
SERM), REACTing-INSERM, the University of Paris Cite and ´
Imagine Institute, Battersea & Bowery Advisory Group, and
William E. Ford, General Atlantic’s Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic’s Co-President,
Managing Director and Head of Business in EMEA, and the
General Atlantic Foundation. I. Meyts is a senior clinical researcher at FWO Vlaanderen; I. Meyts is funded by the European
Research Council under HORIZON-HLTL-2021-ID: 101057100
"Undine," KU Leuven C16/18/007, and FWO grant G0B5120N
(DADA2). L.D. Notarangelo and H.C. Su (members of the COVID
Human Genetic Effort) were supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. P. Bastard was supported by the French
Foundation for Medical Research (FRM, EA20170638020). P.
Bastard and T. Le Voyer were supported by the MD-PhD program
of the Imagine Institute (with the support of the Fondation
Bettencourt-Schueller). P. Bastard was supported by the “Poste
CCA-INSERM-Bettencourt” (with the support of the Fondation
Bettencourt-Schueller). S. Okada was supported by MEXT/JSPS
KAKENHI (grant numbers 22H03041 and 22KK0113) and AMED
(grant numbers JP21fk0108436 and JP22fk0108514). L.I. Gonzalez-Granado is supported by the Instituto de Salud Carlos III
(ISCIII) through the project FIS-PI21/01642 and cofunded by the
European Union. D.C. Vinh is supported by a Fonds de Recherche
du Quebec - Sant ´ e, Senior Clinician-Scientist scholar award. ´
Q. Pan-Hammarstrom was funded by the Swedish Research ¨
Council, and the Knut and Alice Wallenberg Foundation. K. Kisand’s laboratory was funded by the Estonian Research Council
grants PRG1117 and PRG1428. This study also received support
from ISCIII (TRINEO: PI22/00162; DIAVIR: DTS19/00049; ResviOmics: PI19/01039 [A. Salas]; ReSVinext: PI16/01569 [F. Martinón-Torres]; Enterogen: PI19/01090 [F. Martinón-Torres]);
OMI-COVI-VAC (PI22/00406 [F. Martinón-Torres] jointly financed by FEDER), GAIN: Grupos con Potencial de Crecimiento
(IN607B 2020/08 [A. Salas]); ACIS: BI-BACVIR (PRIS-3 [A.
Salas]), and CovidPhy (SA 304 C [A. Salas]); and consorcio Centro
de Investigación Biomedica en Red de Enfermedades Respira- ´
torias (CB21/06/00103; F. Martinón-Torres); GEN-COVID
(IN845D 2020/23, F. Martinón-Torres) and Grupos de Referencia Competitiva (IIN607A2021/05, F. Martinón-Torres). The
study was funded by ISCIII (COV20_01333, COV20_01334, PI16/
00759, PI18/00223, PI19/00208, PI20/00876, and PI21/00211), the
Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/
FEDER, EU), the Fundación Canaria Instituto de Investigación
Sanitaria de Canarias (FIISC19/43, PIFIISC22/27), Grupo DISA
(OA18/017), Fundación MAPFRE Guanarteme (OA21/131), Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas
cient´ıficas del ITER para colaborar en la lucha contra la COVID-19”).
A. Pujol is supported by ACCI20-759 CIBERER, H2020
Marató TV3 COVID 2021-31-33, the HORIZON-HLTH-2021-
ID: 101057100 (UNDINE), the Horizon 2020 program under
grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342),
and the CERCA Program/Generalitat de Catalunya. This research is supported by the European Reference Network for
Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases. Open Access funding provided by Rockefeller
University., Peer reviewed